Zydus Lifesciences has shared its Integrated Annual Report for the financial year 2025-26. The report shows one of the strongest years in the company’s history. It highlights record revenue, major business expansion, new acquisitions, and steady progress in research. The company also explains how it continues to build its presence across global markets while focus remains on new medicines, better healthcare, and long-term business growth.
The annual report gives investors, customers, and industry experts a clear picture of the company’s achievements during the year. It also explains how Zydus plans to strengthen its position in the pharmaceutical industry through innovation, technology, and strategic investments.
Record Revenue Marks a Strong Financial Year
One of the biggest highlights of the report is the record financial performance. Zydus Lifesciences achieved its highest annual revenue so far, which reflects strong demand across several business segments.
The company reported revenue from operations of ₹7,587 crore during the fourth quarter of FY2025-26. This represents a 16 percent increase compared to the same quarter of the previous year. The strong quarterly performance also helped the company achieve its best full-year revenue in its history.
This growth came from several sources. The company saw solid demand for its medicines in India. Its United States generics business also performed well. Specialty medicines and international operations made an important contribution to the overall revenue. Strong performance across different business areas helped the company maintain steady growth despite changes in the global healthcare market.
Growth Came From Multiple Business Segments
The report explains that revenue growth did not depend on just one market. Instead, Zydus received support from several business divisions at the same time.
Its domestic formulations business remained an important source of revenue. The company also continued to strengthen its position in the United States through its generics portfolio. Specialty medicines gained wider acceptance, while international markets delivered healthy business growth.
This balanced approach reduced dependence on a single product or region. It also helped the company build a stronger and more stable business model.
Strategic Acquisitions Expanded Business Strength
Another major achievement during FY2025-26 was the completion of important acquisitions.
One of the most notable deals was the acquisition of Agenus’ Contract Development and Manufacturing Organization (CDMO) business. This move expanded Zydus Lifesciences’ biologics manufacturing capabilities in the United States.
The acquisition supports the company’s long-term plan to become a stronger player in biologics and advanced pharmaceutical manufacturing. It also gives Zydus additional production capacity and improves its ability to serve customers across international markets.
The report explains that these acquisitions are not only about business expansion. They also help the company improve technology, manufacturing quality, and future product development.
Innovation Remained at the Heart of the Business
Innovation continued to play a central role during the financial year.
Zydus Lifesciences maintained strong investment in research and development. The company believes that continuous research is necessary to create new medicines and improve treatment options for patients around the world.
The annual report highlights progress across several important research areas. These include specialty medicines, biologics, vaccines, and novel therapies. Each of these areas has the potential to support future business growth while also meeting important healthcare needs.
The company also made progress with several proprietary drug candidates. These developments show that Zydus continues to build a strong pipeline for future products.
Progress in Regulatory Approvals
The company also achieved important milestones with regulatory approvals.
During FY2025-26, Zydus received multiple approvals from the United States Food and Drug Administration (US FDA). These approvals allow the company to introduce new pharmaceutical products into one of the world’s largest healthcare markets.
Regulatory approvals remain an important part of business success in the pharmaceutical industry. Every approval expands product availability and creates new opportunities for revenue growth.
The annual report also notes that the company continued work on several products that remain under development, which may support future expansion once approvals become available.
Stronger Presence Across Global Markets
The report highlights the company’s steady international expansion.
Zydus Lifesciences now operates more than 30 manufacturing facilities worldwide. These facilities help the company supply medicines to regulated and emerging markets across different regions.
Global expansion has become an important part of the company’s business strategy. A wider international presence allows Zydus to reach more patients while also reducing dependence on any single country or market.
The company continues to strengthen its operations in regulated markets where high manufacturing standards and strict quality requirements remain essential.
Focus on Long-Term Sustainability
The Integrated Annual Report also places strong attention on environmental, social, and governance initiatives, commonly known as ESG.
The company explains that business growth should also create value for society. Because of this, Zydus continues to invest in environmental responsibility, employee welfare, corporate governance, and community healthcare.
The report describes efforts to improve sustainability across operations while also supporting employees through development programs and workplace initiatives.
Healthcare support for communities also remains an important part of the company’s long-term vision. These efforts reflect the belief that business success and social responsibility should move forward together.
Research Investment Supports Future Growth
The pharmaceutical industry depends heavily on continuous research. New medicines require years of scientific work before they reach patients.
The report shows that Zydus Lifesciences continued to allocate a significant share of its revenue toward research and development during FY2025-26. This investment supports future innovation and helps the company remain competitive in a fast-changing healthcare industry.
Research across biologics, vaccines, specialty medicines, and advanced therapies could open new opportunities over the coming years. The company believes these investments will strengthen both patient care and long-term financial performance.
A Clear Vision for the Future
The annual report presents a clear roadmap for future growth.
Zydus Lifesciences plans to build on its recent achievements by expanding its innovation pipeline, strengthening manufacturing capabilities, and increasing its presence in international markets.
The successful integration of newly acquired businesses will remain an important priority. The company also expects continued progress from its research programs and proprietary drug candidates.
Strong financial performance provides additional resources that can support future investments in technology, product development, and manufacturing capacity.
Conclusion
The FY2025-26 Integrated Annual Report shows that Zydus Lifesciences completed an exceptional year. Record revenue, supported by ₹7,587 crore in fourth-quarter revenue from operations and 16 percent year-on-year growth, reflects the strength of its diversified business. Progress across domestic formulations, the United States generics market, specialty medicines, and international operations created a solid foundation for success.
Strategic acquisitions, including the purchase of Agenus’ CDMO business, expanded the company’s biologics manufacturing capabilities in the United States. At the same time, steady investment in research, progress in biologics, vaccines, specialty medicines, and novel therapies, along with multiple US FDA approvals, demonstrated the company’s commitment to innovation.
With more than 30 manufacturing facilities worldwide, a growing global footprint, and continued focus on sustainability and responsible business practices, Zydus Lifesciences enters the next financial year with strong momentum. The report reflects a company that combines financial strength, scientific research, strategic expansion, and long-term planning to create lasting value for patients, partners, shareholders, and the healthcare industry.
